Under the heading "Data extraction and quality assessment", second paragraph third line, the words "hazard ratio" should read as "hormone receptor".
In the original publication of the article, the authors' affiliation was published incorrectly. The corrected affiliation is given in this correction. The author also found few corrections in the article which are given below:
Department of Medical Oncology, National Cancer Centre/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, #17 Panjiayuan Nanli, Beijing, China.
Under the heading "Data extraction and quality assessment", second paragraph third line, the words "hazard ratio" should read as "hormone receptor".
Under the heading "Statistical analysis", fourth line "I 2 < 50%" should read as "I 2 ≤ 50%". Under the heading "Discussion", the sentence that reads as "Similar results were observed in the two studies suggesting that fulvestrant is more effective in patients with estrogen and/or progesterone receptor positive" should read as "Similar results were observed in the two studies suggesting that fulvestrant is more effective in patients with estrogen and progesterone receptor positive".
Under the heading "Discussion", second paragraph, the sentence that reads as "Supporting these results, in addition to the favorable effect of fulvestrant over other aromatase inhibitors" should read as "Supporting these results, in addition to the favorable effect of fulvestrant over aromatase inhibitors".
Under the heading "Discussion", second paragraph, the sentence that reads as "Therefore, most of the recent analysis with updated trials, including our work, has shown a more efficacy of fulvestrant over other aromatase inhibitors" should read as "Therefore, most of the recent analysis with updated trials, including our work, has shown a more efficacy of fulvestrant over aromatase inhibitors".
